首页> 外文期刊>Biochemical and Biophysical Research Communications >Glycosylation is a novel TGF beta 1-independent post-translational modification of Smad2
【24h】

Glycosylation is a novel TGF beta 1-independent post-translational modification of Smad2

机译:糖基化是一种新的TGFβ1-Indementy翻译后Smad2的翻译后改性

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Smad2 is a crucial component of intracellular signaling by transforming growth factor-beta (TGF beta ). Here we describe that Smad2 is glycosylated, which is a novel for Smad2 post-translational modification. We showed that the Smad2 glycosylation was inhibited upon treatment of cells with 17 beta-estradiol, and was enhanced in cells in a dense culture as compared to cells in a sparse culture. The Smad2 glycosylation was not dependent on the C-terminal phosphorylation of Smad2, and was not affected by TGF beta 1 treatment of the cells. Smad2 was glycosylated at multiple sites, and one of the predicted sites is Serine110. Thus, Smad2 is glycosylated, and this post-translational modification was modulated by 17 beta-estradiol but not by TGF beta 1. (C) 2019 Elsevier Inc. All rights reserved.
机译:Smad2是通过转化生长因子-β(TGFβ)细胞内信号传导的关键组分。 在这里,我们描述了Smad2是糖基化的,这是一种用于Smad2后翻译改性的新颖。 我们表明,在用17β-雌二醇处理细胞后,抑制Smad2糖基化,并且与稀疏培养物中的细胞相比,在致密的培养物中被浓密的细胞增强。 Smad2糖基化不依赖于Smad2的C末端磷酸化,并且不受TGFβ1治疗细胞的影响。 Smad2在多个位点糖基化,其中一个预测的位点是丝氨片110。 因此,Smad2是糖基化的,并且这种翻译后修饰由17β-雌二醇调节,但不是TGFβ1.(c)2019年Elsevier Inc.保留所有权利。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号